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ABSTRACT 
METHYLGLYOXAL INFLUENCES DEVELOPMENT OF CAENORHABDITIS 
ELEGANS VIA HETEROCHRONIC PATHWAY  
May 2017 
JIAYING WANG 
B.S., ZHEJIANG UNIVERSITY OF TECHNOLOGY 
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Yeonhwa Park  
 
Methylglyoxal is a highly reactive dicarbonyl compound, which is widely 
distributed in food products and beverages, and is particularly high in Manuka honey. In 
addition to its antibacterial effects, methylglyoxal is also known as a major precursor of 
advanced glycation end products (AGEs), that produces altered macromolecules (such as 
proteins and DNA), leading to abnormal physiological changes. However, the effects of 
methylglyoxal on development is unclear. Thus, this study aimed to determine the role of 
methylglyoxal in this aspect using Caenorhabditis elegans (C. elegans). Treatment of 
methylglyoxal at 0.1 mM and 1 mM for 48 h significantly inhibited development of C. 
elegans and reduced pumping rate. Activity, measured by moving speed, was increased 
with 0.1 mM methylglyoxal, but reduced with 1 mM methylglyoxal. Lifespan of C. 
elegans was not influenced by methylglyoxal at 0.1 mM, but was shortened at 1 mM 
Treatment methylglyoxal on the mutant, lin-41, which has a precocious phenotype, could 
alleviate the implication on wild-type worms. These results suggested that methylglyoxal 
significantly influenced the development of C. elegans through the heterochronic 
 vi 
 
pathway.  
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 CHAPTER 1  
INTRODUCTION 
 Methylglyoxal is the natural active component of Manuka honey, well known for its 
antibacterial function (Degen et al., 2012). However, it is also reported to be associated 
with diseases including diabetes, atherosclerosis, and neurological disorders (Vistoli et al., 
2013). Previous in vitro research found that methylglyoxal exhibited an autoxidative 
character, which could generate reactive oxygen species (ROS) in the mitochondria, and 
it is susceptible to alter the structure and functions of macromolecules, such as protein 
and nucleotides (Lo et al., 1994; Singh et al., 2001). Animal studies further investigated 
the effects of methylglyoxal in biological system. Although there were inconsistent 
results of no effects or anti-cancer effects of methylglyoxal in vivo, the majority of results 
concluded that methylglyoxal could induce weight-loss, inactivity, certain types of 
cancers, or even death in a dose-dependent manner (Dakin and Dudley, 1913; Sjolemma 
and Seekles, 1926; Nagao et al., 1986; Kalapos et al., 1991; Choudhary et al., 1997; Golej 
et al., 1998). In addition, aging and neurological disorders induced by methylglyoxal are 
the most investigated problems and several pathways in biological system regulated by 
methylglyoxal metabolism were previously identified (Bonifati et al., 2003; Morcos et al., 
2008;Lee et al., 2012). However, to our best knowledge, there are no reports on effects of 
methylglyoxal in the animal development. Therefore, we explored the effect of 
methylglyoxal on development and determined the underlying mechanism. 
Caenorhabditis elegans is an animal model with a short lifespan of about 21 days 
(Leung et al., 2008). The development time of C. elegans only requires 48 h after 
hatching at 20ºC (Leung et al., 2008). C. elegans is the first animal to have its genome 
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completely sequenced, and more than 65% of the genes associated with human disease 
are conserved (Kaletta and Hengartner, 2006). Thus, we choose this model to conduct the 
current project.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1. Methylglyoxal 
2.1.1. Introduction 
Methylglyoxal is a naturally occurring component of Manuka honey. It is a 
commercial factor used for classification of premium honey products as the so-called 
Unique Manuka Factor (UMF), based on in vitro anti-microbial assays (Mavric et al., 
2008). It is also known to be one of the most important components in the formation of 
advanced glycation end products (AGEs) (Shinohara et al., 1998), which is associated 
with diseases, such as diabetes, atherosclerosis, and neurological disorders (Vistoli et al., 
2013). Methylglyoxal is a yellowish, clear, and water-soluble liquid at room temperature, 
and it is also known as pyruvaldehyde, acetyl formaldehyde, or propanedione (Figure 1). 
It contains two carbonyl groups (C=O): an aldehyde and a ketone. Therefore, it is reactive 
because aldehyde is readily oxidized to carboxylic acids (Corey et al., 1968). 
 
Figure 1.  Methylglyoxal chemical structure 
 
2.1.2. Methylglyoxal formation 
The origin of methylglyoxal can be separated into exogenous, from food and 
beverages, and endogenous, from enzyme-catalyzed and spontaneous reaction. Overall 
levels of methylglyoxal are a balance between exogenous and endogenous formation and 
elimination of methylglyoxal in the biological system. There are a great number of 
publications reporting the effects of methylglyoxal in the biological system in past 
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decades. 
2.1.2.1. Exogenous sources 
Except for honey, its only natural source, methylglyoxal can be formed in many 
food products and beverages derived from carbohydrates, amino acids, lipids, and 
microorganisms during food processing, cooking, and storage. Average levels of 
methylglyoxal in food are summarized in Table 1.  
It is known that the retro-aldol condensation and autoxidation of sugar results in 
methylglyoxal, with higher levels found in monosaccharides than disaccharides. As 
mentioned, honey (Table 1) is a great source of methylglyoxal (0.4 – 5.4 mg/kg) due to 
simple sugar degradation during storage (Weigel et al., 2004). In addition, the Maillard 
reaction, which is a reaction between amino acids and reducing sugars, can produce 
methylglyoxal (Martins et al., 2003). As known in the Maillard reaction, temperature 
contributes significantly to methylglyoxal formation (Martins et al., 2003). Thirdly, 
decomposition of different lipids during food storage and processing could generate 
methylglyoxal in food samples (Fujioka and Shibamoto, 2004). Furthermore, 
photodegradation of lipids and related compounds yield methylglyoxal as a degradation 
product (Niyati-Shirkhodaee and Shibamoto, 1993). Lastly, methylglyoxal can be formed 
by microorganisms during fermentation processing, such as alcoholic drinks and dairy 
products. Methylglyoxal is synthesized by Saccharomyces cerevisiae during alcoholic 
fermentation as well as by Oenococcus oeni (Leuconostocoenos) during malolactic 
fermentation (Yadav et al., 2005).  
2.1.2.2. Endogenous source 
In addition to food, methylglyoxal can be formed in biological systems 
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endogenously. Both enzymatic and non-enzymatic pathways have been identified for 
endogenous methylglyoxal formation (Vander Jagt and Hunsaker, 2003). Enzymatic 
pathways include reactions involved in glycolytic bypass, acetone metabolism, and amino 
acid breakdown (Cooper, 1984; Kalapos, 1999; Ko et al., 2005). Non-enzymatic 
pathways include acetol autoxidation, lipid peroxidation and others (Nemet et al., 2006). 
Table 1 Methylglyoxal concentration of some food 
Food or beverage 
Methylglyoxal 
concentration 
(mg/kg) Reference 
Sweetened cola (sucrose-
sweetened) 
0.007 to 0.32 (Tan et al., 2008) 
 
Sweetened cola (high fructose corn 
syrup-sweetened) 
0.23 to 1.4 (Tan et al., 2008) 
Fruit juice 0.05 (Degen et al., 2012) 
Fermented beverages (yogurt, 
alcoholic beverages, and soy sauce) 
0.02-7.6 (Degen et al., 2012) 
Jams, jellies and sweeteners 4 (Degen et al., 2012) 
Coffee 23 (Degen et al., 2012) 
Bread and cookies 210 (Degen et al., 2012) 
Commercial honey 0.4-5.4 (Degen et al., 2012) 
Manuka honey 740 (Mavric et al., 2008) 
   
2.1.2.2.1. Glycolytic Bypass 
Glycolytic bypass is the major pathway of methylglyoxal formation endogenously, 
and is catalyzed by methylglyoxal synthase (Chakraborty et al., 2014). If there is too 
much sugar, one of the intermediates of glycolysis, glyceraldehyde-3-phosphate will be 
converted to dihydroxyacetone phosphate by triosephosphate isomerase, and then 
subsequently converted to methylglyoxal by methylglyoxal synthase (Ahmed et al., 
2003a). It has been proven that increased concentration of dihydroxyacetone phosphate is 
 6 
 
associated with increased levels of methylglyoxal (Ahmed et al., 2003a).  
2.1.2.2.2. Acetone Metabolism  
Diabetes is known to have high levels of ketone bodies and among them, 
acetoacetate is regarded as a characteristic feature of diabetes (Kupari et al., 1995; Veech, 
2004). Acetoacetate is converted to acetone, then subsequently to hydroxyacetone by 
Cytochrome P450 and acetol monooxygenase, respectively. The latter is oxidized to 
methylglyoxal (Rabbani et al., 2016). Thus, it is known that diabetes has higher levels of 
methylglyoxal.  
2.1.2.2.3. Amino Acid Breakdown 
 Another non-glycolytic formation of methylglyoxal is from amino acid breakdown, 
particularly from L-threonine and L-glycine. L-Threonine is initially oxidized by 
threonine dehydrogenase into oxobutyrate, then to aminoacetone (Shimizu et al., 2005). 
L-Glycine is converted to aminoacetone by acetyl aminoacetone synthase with CoA. 
Methylglyoxal is the end product of aminoacetone degradation, which is catalyzed by 
amino oxidase (Shimizu et al., 2005). 
2.1.3. Methylglyoxal elimination 
Methylglyoxal can be eliminated by four enzymes: the glyoxalase system, aldose 
reductase (ALRs), aldehyde dehydrogenase (ADHs), and 2-oxoaldehyde dehydrogenase 
(2-ODHs) (Nemet et al., 2006). 
The glyoxalase system comprises two enzymes; glyoxalase I and glyoxalase II 
(Thornalley, 1990). This is the major enzyme system for the elimination of methylglyoxal. 
Methylglyoxal is non-enzymatically converted to hemithioacetal with glutathione and 
subsequently catalyzed by glyoxalase I to S-D-Lactoylglutathione (Thornalley, 1995). S-
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D-lactoylglutathione is converted to D-lactate by glyoxalase II, and further metabolized 
to pyruvate by 2-hydroxyacid dehydrogenase at the mitochondria (Thornalley, 1996).  
Apart from the glyoxalase system, aldose reductases could convert methylglyoxal 
into acetol and subsequently reduce it to propanediol (Vander Jagt and Hunsaker, 2003). 
In addition, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenases are 
known to catalyze methylglyoxal to pyruvate (Vander Jagt and Hunsaker, 2003).  
2.1.4. Methylglyoxal research in vitro 
(Kisch, 1932) reported that methylglyoxal decreased oxygen consumption in Jensen-
sarcoma cells. (Thornalley et al., 1984) found that methylglyoxal was autoxidative, 
generated reactive oxygen species (ROS), modified mitochondrial proteins, and led to 
apoptosis of rat osteoblasts. However, methylglyoxal was cytotoxic to rat hepatocytes 
even under anaerobic conditions, which suggested that the autoxidation of methylglyoxal 
cannot explain its toxicity completely (Kalapos et al., 1993; Chan et al., 2007).  
Methylglyoxal is susceptible to react irreversibly with protein, nucleotides, and basic 
phospholipids, which is verified in in vitro experiments (Thornalley, 1995; Ahmed et al., 
2003b). This process is called dicarbonyl glycation and the adducts formed are AGEs 
(advanced glycation end-products). AGEs are known to have altered macromolecule 
structure and functions, and to be associated with complications of diabetes, 
atherosclerosis, and altered immune response (Chakraborty et al., 2014; Thornalley et al., 
1999).  
Methylglyoxal targets arginine residues, forming hydroimidazolone adducts (MG-
H1), which is one of the major AGEs in physiological systems (Rabbani and Thornalley, 
2012). There are also minor lysine-derived AGEs: such as CEL [Nε-(1-carboxyethyl) 
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lysine], argpyrimidine, and trace levels of MOLD (MG-derived lysine dimer cross-link) 
(Rabbani and Thornalley, 2012). Protein adducts bind specifically to cell-surface 
receptors, which is a specific receptor for AGEs, to activate cell dysfunction (Bierhaus et 
al., 2005). Methylglyoxal also forms DNA adducts in physiological systems. The major 
adduct is an imidazopurinone MGdG {3-(2-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-
6/7-methylimidazo-[2,3-b] purine-9(8) one} and a minor adduct CEdG [N2-(1-
carboxyethyl)-deoxyguanosine], which were associated with DNA instability and 
resulted in mutagenesis (Thornalley and Rabbani, 2010). 
2.1.5. Methylglyoxal research in vivo 
The research of methylglyoxal in vivo is summarized in Table 2. The first in vivo  
experiment of methylglyoxal reported that the subcutaneous injection of this compound 
had no effects on rabbits (Dakin and Dudley, 1913). (Apple and Greenberg, 1968) 
demonstrated methylglyoxal had an anti-cancer effect in mice. However, the reduced 
psychomotoric activity of methylglyoxal was first reported in 1926 as the adverse effect 
of methylglyoxal in rabbits (Sjolemma and Seekles, 1926). Others reported that 
methylglyoxal injected rats were found to develop skin cancers (Nagao et al., 1986). The 
acute lethal dose of methylglyoxal was 800 mg/kg body weight, while a lower dose of 
methylglyoxal led to a decrease of liver weight, inactive and/or irregular muscle 
movement (Kalapos et al., 1991; Choudhary et al., 1997). Oral administration of 
methylglyoxal targeted kidneys, accumulating methylglyoxal collagen that thickened 
glomerular basement membrane with an obligatory morphological change (Golej et al., 
1998). 
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Table 2. Methylglyoxal research in vivo 
Time Animal 
models 
Treatment Methylglyoxal 
dose 
Conclusion Reference 
1913 Rabbits Subcutaneous 
injection 
Unknown No effects (Dakin and 
Dudley, 
1913) 
1926 Rabbits Subcutaneous 
injection 
Unknown Without appetite and 
depressed 
 (Sjolemma 
and 
Seekles, 
1926) 
1968 Male 
swiss 
albino 
mice 
Unknown Unknown Anti-cancer effects 
on variety of cancers 
(Apple and 
Greenberg, 
1968) 
1986 Male & 
female 
fischer 
344 rats  
Skin injection 2 mg/animal Developed cancers (Nagao et 
al., 1986) 
1991 Male 
CFLP 
mice 
Intraperitoneal 
injection 
Unknown Slowed movement 
and ataxy 
(Kalapos et 
al., 1991)  
1991,
1997 
Male 
swiss 
albino 
mice 
Intraperitoneal 
injection 
800 mg/kg 
body weight  
Lethal within 4 h (Kalapos et 
al., 1991; 
Choudhary 
et al., 1997) 
1991,
1997 
Male 
swiss 
albino 
mice 
Intraperitoneal 
injection 
Less than 800 
mg/kg body 
weight 
Decreased liver 
weight after 24 h 
(Kalapos et 
al., 1991; 
Choudhary 
et al., 1997) 
1991 Male 
swiss 
albino 
mice 
Intraperitoneal 
injection 
400 mg/kg 
body weight 
Slight histological 
changes in livers 
(vacuole formation 
in the centrilobular 
areas) 
(Kalapos et 
al., 1991; 
Choudhary 
et al., 1997)  
1998 Female 
OF-1 
mice 
Oral 
administration  
50 mg/kg body 
weight 
Collagen 
accumulation in 
kidneys; glomerular 
basement membrane 
thickening 
(Golej et 
al., 1998) 
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2.1.6. Strategies for minimizing methylglyoxal 
Based on the information above, strategies for prevention of methylglyoxal toxicity 
could be by: (a) prevention of methylglyoxal formation, (b) scavenging of methylglyoxal 
directly, and (c) enhancing the expression of enzymes of methylglyoxal elimination, 
particularly glyoxalase-1 (Rabbani et al., 2016). First, the formation of methylglyoxal can 
be reduced by a high dose of thiamine supplementation by decreasing the activity of 
triosephosphate isomerase, a key enzyme for methylglyoxal production. Secondly, 
scavengers, such as aminoguanidine, phenacylthiazolium derivatives, and arginine-rich 
peptides, can be used to scavenge methylglyoxal directly. However, it is not clear that 
these products are without any toxic effects (Rabbani et al., 2016). Lastly, enhancing 
glyoxalase-1, ALRs, and ADHs, which are the key enzymes for eliminating 
methylglyoxal, can reduce methylglyoxal levels. Based on reports that the transcription 
factor, Nrf2 (nuclear factor-erythroid 2-related factor-2), regulates the above enzymes 
and is downregulated during aging, it is possible that by targeting Nrf2, elimination of 
methylglyoxal can be enhanced (Rabbani et al., 2016).  
 
2.2. Caenorhabditis elegans 
2.2.1. General characteristics of C. elegans 
C. elegans is a small (1~1.5 mm as an adult), eukaryotic, multi-organ, and free-
living nematode found worldwide. C. elegans is easily cultivated on agar plates and 
typically feeds on non-pathogenic Escherichia coli (E. coli). The body and neural 
circuitry is anatomically simple, with approximately 1,000 somatic cells and 300 neurons 
 11 
 
(Giles and Rankin, 2009; Dimitriadi and Hart, 2010). The transparent body of this worm 
makes it easy to view the tissue in all stages of development under an optical microscope. 
Normally, a wild-type C. elegans has a short lifespan of about 21 days, and reaches 
adulthood within 38~46 h after hatching at 20◦C. C. elegans produces large broods of 300 
progenies and each hermaphrodite has two ovaries, oviducts, a cavity for storing sperm 
(spermatheca), and a uterus (L’Hernault, 2009). Most importantly, C. elegans is the first 
animal to have its genome completely sequenced, and more than 65% of the genes 
associated with human disease are conserved in the worm (Greer et al., 2008). In addition, 
C. elegans exhibits very complicated functions varying from feeding to locomotion 
suggesting further application for in vivo research. 
2.2.2. C. elegans as an animal model for development research 
C. elegans has been used in studies for cell biology, genetics, and neurobiology 
since 1965. Between 1970 and 1980, the complete cell lineage of this worm, from the 
fertilized egg to adult, was characterized by laser ablation and microscopy (Sulston et al., 
1983). (White et al., 1986) constructed the entire nervous system by electron microscopy 
and serial sectioning, and (Coulson et al., 1991) started to work on genetic and genomic 
data collection. Bioassays to assess the impact of inherent or environmental changes on C. 
elegans can be carried out through different endpoints. These endpoints can be grouped 
according to their effects on biological parameters, such as lethality, growth, locomotion, 
reproduction, etc. It is also possible to use molecular markers to determine oxidative 
stress, changes in gene or protein expression, DNA damage, or green fluorescence 
protein (GFP) expression (Tejeda-Benitez and Olivero-Verbel, 2016). 
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2.2.2.1. Physiological parameters of C. elegans 
Among worms’ development parameters, body length of synchronous worms before 
and after exposure can be used to evaluate the effect of a compound in the growth of the 
nematode. The developmental stage of C. elegans can be determined by: L1, four or 
fewer gonad cells, L2, over four gonad cells which have begun to spread along the length 
of the animal, L3, extension of the gonad, and vulvae morphogenesis has started, L4, a 
dorsal rotation of the gonad, and adults, observable eggs (Helmcke et al., 2009). The 
deterioration of the neural system during development can be evaluated by locomotion, 
which includes head thrash, body bend frequency, and basic movements (Yu et al., 2013). 
A head thrash is defined as a change in the direction of bending in the body, observed as 
a change in direction of the upper pharynx along the Y-axis, assuming that the nematodes 
are moving along the X-axis. The body bend frequency refers to the frequency of 
oscillations between adjacent body segments. The basic movement is measured as 
average speed of worm crawling or swimming (Yu et al., 2013). Brood size is the 
endpoint of development and is used to evaluate the reproduction of the nematodes. 
Moreover, the gonad size, obtained by image analysis under a microscope, has been 
utilized to evaluate the effects on reproductive organs and the rate of egg laying, which 
means the number of eggs laid in 1 h is a biomarker of reproduction (Jadhav and Rajini, 
2009;Shashikumar and Rajini, 2010;Wu et al., 2011). The lifespan is defined as the 
period between the L4 larval stage and death. At 20°C, the wild type C. elegans has an 
average lifespan of around 2–3 weeks (Yunhui et al., 2009;Shen et al., 2009;Wang et al., 
2010;Zhuang et al., 2014). 
2.2.2.2. Development pathway of C. elegans 
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After embryogenesis, C. elegans develops through four larval stages (L1–L4) before 
reaching sexual maturity. The proper temporal control of stage-specific events of cell 
division, cell behavior, and differentiation through four larval stages are controlled by the 
heterochronic pathway, which is comprised by a number of microRNA and protein 
regulators (Figure 2). The precise scheduling for the stage-specific events and temporal 
controls of cell division, differentiation, and morphogenesis is regulated by a complex but 
organized schedule of heterochronic gene activities for animal normal development. 
Adult stage is also regulated by the heterochronic pathway to exit the cell cycle, fuse with 
neighboring hypodermal seam cells, and generate cuticle alae (Sulston and Horvitz, 1977; 
Reinhart et al., 2000). However, improper development can result in either retarded or 
precocious development, by repeating early developmental events or by expressing late 
developmental events at early stages, respectively. 
Figure 2. Expression of some heterochronic genes during larval development (Lee et al., 1993; Rougvie 
and Ambros, 1995; Slack et al., 2000) . 
 
2.2.2.2.1. lin-14  
The gene lin-14 encodes a novel protein, LIN-14, in C. elegans, whose activity is 
required for the timings of vulva cell group division during postembryonic development 
(Lee et al., 1993). The normal L1 stage requires a high level of lin-14 activity and the 
execution of L1 stage to later stages depends essentially on the decrease of lin-14 
expression. In addition, lin-14 acts with lin-4 to govern L1 cell fates, and then interacts 
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with lin-28 to regulate L2 developmental events (Ambros and Horvitz, 1984). The lin-14 
null (0) mutant misses the expression of L1 specific events, thus becoming precocious 
compared to the normal developmental program. In the contrary, lin-14 gain-of-function 
mutant displays a retarded phenotype (Ambros and Horvitz, 1984). 
2.2.2.2.2. lin-4 
The lin-4 encodes a small non-coding temporal RNA (stRNA) and is a critical gene 
in the early stages of development in diverse cell types of C. elegans (Lee et al., 1993). 
Expression of lin-4 begins at the end of the L1 larval stage and increases to highest levels 
in adult animals (Ambros and Horvitz, 1984). Repression translation of the lin-14 and 
execution L1 stage is the function of lin-4 (Ambros and Horvitz, 1984). Thus, lin-4 loss-
of-function mutation, lin-4(e972), displays reiterations of L1 events at late developmental 
stages (Ambros and Horvitz, 1984). 
2.2.2.2.3. lin-28 
For L2 stage specific developmental events, the heterochronic gene, lin-28, plays a 
critical role. In addition, LIN-28 is an RNA binding protein, best known for regulating 
the maturation of the microRNA let-7 (Rougvie and Ambros, 1995;Reinhart et al., 
2000;Pepper et al., 2004). However, lin-28 expression was not detectable after the L3 
stage. Several researches confirmed that the function of lin-28 at the L2 stage was a 
premise for larva-to-adult transition, which means lin-28 interacted with other 
heterochronic genes to affect the larval-to-adult transition (Rougvie and Ambros, 
1995;Reinhart et al., 2000;Pepper et al., 2004). Thus, lin-28 loss-of-function mutant not 
only skips the L2 stage seam cell proliferative program, but also causes precocious 
execution of the larva-to-adult transition, which presents the phenotype of lateral 
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hypodermal seam cells ceasing division, differentiation, and adult alae production 
(Ambros and Horvitz, 1984). 
2.2.2.2.4. let-7 family microRNAs  
The let-7 family microRNAs comprise let-7, a critical regulator of developmental 
timing events at the larval-to-adult transition, and three other microRNA genes: mir-48, 
mir-84, and mir-241, which regulate L2-to-L3 developmental timing decisions. The 
retarded behaviors, like extra seam cell divisions, could be found in diverse cell types 
from the L2 to L3 transition in double mutants mir-48: mir-241, mir-48: mir-84, and 
triple mutants (Abbott et al., 2005). However, normal phenotype was observed in the 
singly mutant worms with deletions of mir-48, mir-84, or mir-241 and the double mutant 
mir-84: mir-241.  
The let-7 functions as a temporal switch between larval and adult fates since the 
expression of let-7 is only detected at L4 and adult stages. Thus, the let-7 loss-of-function 
mutant reiterates larval patterns of hypodermal cell division during the L4-to-adult 
transition. Besides, it undergoes a supernumerary molt to an extra stage, L5, before adult. 
In contrast, the overexpression of let-7 causes precocious adult fates during larval stages, 
which means hypodermal cells exit the cell cycle ahead of time. 
2.2.2.2.6. lin-41 
The lin-41 encodes a RING-finger B-box Coiled-coil (RBCC) protein and is 
negatively regulated by the let-7 microRNA during L4 and adult stages (Solomon et al., 
2008). In addition, lin-41 represses lin-29 during late larval stages, which prevents 
terminal differentiation of hypodermal seam cells. Thus, lin-41 loss-of-function mutants 
display premature phenotypes from the L3 larval stage that seam cells adopt the adult fate 
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to secrete alae ahead of time, but does not affect L1 and L2 stage fates (Reinhart et al., 
2000; Solomon et al., 2008).  
2.2.2.2.7. lin-29 
The lin-29, a zinc-finger transcription factor, which regulates adult-specific patterns 
of cell lineage and cell differentiation, acts as a downstream of heterochronic genes, let-7 
and lin-41 (Rougvie and Ambros, 1995; Reinhart et al., 2000). Furthermore, lin-29 is the 
most direct known regulator of the larval to adult transition in C. elegans (Rougvie and 
Ambros, 1995). Thus, lin-29 activity is essentially required for the execution of almost all 
aspects of the larval to adult transition, particularly for the terminal differentiation of the 
lateral hypodermal seam cells and the formation of the adult cuticle (Rougvie and 
Ambros, 1995). In the lin-29 loss-of function mutant, the seam cells continue to 
synthesize a larval-specific cuticle lacking adult-specific alae, which means the animal 
undergoes supernumerary molts (Ambros and Horvitz, 1984). Interestingly, both the lin-
29 loss-of-function mutant and the let-7 loss-of-function mutant display a retarded 
phenotype, but the former repeats the cell cycles in the L4-stage indefinitely, while let-7 
loss-of-function mutants only repeat once, which indicates lin-29 displays a stronger 
function in the heterochronic pathway than let-7 (Slack et al., 2000). 
 
2.3. Methylglyoxal Research in C. elegans 
The activity of glyoxalase-1 is markedly reduced with age. However, in aging, 
methylglyoxal level, methylglyoxal-derived adducts, and oxidative stress markers, such 
as carboxymethyllysine (CML) and 3-nitrotyrosine, increase dramatically (Morcos et al., 
2008). As reported, over-expression of the glyoxalase-1 ortholog, CeGly 1, could prolong 
C. elegans lifespan by decreasing modification of mitochondrial protein and ROS 
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production (Morcos et al., 2008).  
In humans, protein deglycase, DJ-1, is expressed to protect cells from oxidative and 
exert neuroprotection against Parkinson's Disease (Bonifati et al., 2003; Lee et al., 2012). 
In C. elegans, cDJR-1.1, a DJ-1 ortholog expressed primarily in the intestine, when 
lacking decreased 71% of the enzyme activity for methylglyoxal elimination; cDJR-1.2,  
another DJ-1ortholog, expressed primarily in the head region and leading to the 
significant degeneration of the dopaminergic neurons, when lacking decreased 28% of 
the enzyme activity for methylglyoxal elimination (Bonifati et al., 2003;Lee et al., 2012). 
Thus, these findings imply that cDJR-1.1 and cDJR-1.2 are important in methylglyoxal 
elimination, which could protect worms from methylglyoxal.  
At present, the methylglyoxal research in C. elegans is limited to aging and 
neurological disorders. As an ideal model for development study, C. elegans is a great 
tool to investigate the interaction between methylglyoxal and development. 
 
2.4. Conclusion 
Methylglyoxal, as an active carbonyl compound, can be produced inherently or 
elevated by exogenous sources. In order to minimize its toxicity on aging, development, 
and the nervous system, there are endogenous elimination systems to keep the normal 
metabolic activity. According to previous studies, glyoxalase-1 and DJ-1 are reported as 
essential pathways in methylglyoxal regulation with aging and neurological issues, 
respectively. As for development, C. elegans could be a great model to be used for its 
completed understood genome sequence and heterochronic system. This review 
elucidates the mechanism of methylglyoxal in development of C. elegans. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1. Strains 
The C. elegans strain N2 was used as the wild-type worm. The N2 strain, mutant lin-
41(ma104) I and Escherichia coli (E. coli) OP50 were obtained from the Caenorhabditis 
Genetics Center (CGC), University of Minnesota, USA.  
3.2. Chemicals 
Methylglyoxal aqueous solution was purchased from MP Biomedicals, LLC (Solon, 
OH). 5-fluoro-2′-deoxyuridine (FUdR) was purchased from Sigma-Aldrich Co. (St. Louis, 
MO). Household bleach for synchronization of worms was purchased from a local store 
(The Clorox company, Oakland, CA). Other chemicals were purchased from Thermo 
Fisher Scientific Inc. (Pittsburgh, PA). 
3.3. Worm maintenance 
Synchronized worms were prepared by placing adult worms on a nematode growth 
media (NGM) plate containing a lawn of E. coli OP50. After removing the worm bodies 
using freshly prepared bleach solution, each synchronized egg was transferred to a S-
complete solution in 15 ml conical tubes. When the eggs hatched, concentrated E. coli 
OP50 was added with 0.1 mM or 1 mM methylglyoxal, respectively. All C. elegans 
strains were raised at 25C. 
3.4. Growth rate assay 
For each treatment group, 50 worms were selected randomly and paralyzed with 10 
mM NaN3. The worms were transferred onto NGM plates without a bacterial lawn and 
the developmental stages were identified under an optical microscope. The growth rates 
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were measured as the population ratio of worms at different developmental stages. 
3.5. Pumping rate assay 
         For each treatment, 12 worms were randomly selected and placed on NGM plates 
with a thin layer of E. coli OP50. The number of nematodes’ pharynx contractions was 
counted for 1 min using an optical microscope. Experiments were carried out in 
triplicates. 
3.6. Body size and activity determination 
         For each treatment, 50 worms were randomly selected and placed on low-peptone 
NGM plates. E. coli OP50 were seeded 5 min before tracking. Then worms were allowed 
to acclimate and move for 15 min before video recording. A 1-min recording (7.99 
frames per second) was captured by WormLab Video Capture System (Version 3.1.0, 
MBF Bioscience, Williston, VT, USA). The average moving speed and the body size 
(length and width) were analyzed by WormLab (Version 3.1.0, MBF Bioscience, 
Williston, VT, USA). 
3.7. Lifespan assay 
         Lifespan analysis was carried out at 25°C. Worms were treated with methylglyoxal 
at 0.1 mM and 1 mM from the L4 stage, at which 120 μM 5-Fluoro-2′-deoxyuridine 
(FUdR) was added in HTS Transwell®-96 well permeable plates (Corning Inc., NY). The 
medium was changed twice a week. Plates were shaken for 2 min before counting and 
worm viability was scored every other day until all the worms died. 
3.8. Statistical analysis 
All data were expressed as mean ± standard error (S.E.). Mean differences between 
treated groups and controls were determined by one-way analysis of variance (ANOVA), 
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followed by Dunnett’s test using the Statistical Analysis System (Version 9.4, SAS 
Institute, Cary, NC). A P-value of less than 0.05 was considered significant. 
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CHAPTER 4 
RESULTS AND DISSCUSION 
4.1. Methylglyoxal treatment significantly reduced the lifespan of C. elegans 
The result (Figure 1) showed that the 1 mM methylglyoxal treatment group had a 
significantly reduced maximum lifespan of 21 days, compared to the control (34 days). 
Methylglyoxal at 0.1 mM did not influence the lifespan of wild-type worms. The median 
lifespan was 21, 23, and 11 days in the control, 0.1 mM, and 1 mM treatment groups, 
respectively. These indicated that 1 mM methylglyoxal, but not 0.1 mM, significantly 
accelerated aging compared to control.                 
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Figure 3. Effects of methylglyoxal on survival of C. elegans. Age-synchronized L4 C. elegans were 
cultured in 96-well plates with 0, 0.1 mM, and 1 mM methylglyoxal from the first day of adulthood. The 
number of survivals were recorded every other day. Around 100 worms were raised for each group.  
          
concentration 0.1 mM versus control 1 mM versus control 1 mM versus 0.1 mM 
P- value  Not significant < 0.0001 <0.001 
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4.2. Methylglyoxal treatment significantly delayed the development of C. elegans 
         To determine whether methylglyoxal had any effects on the development of the 
nematodes, the growth rate was analyzed. As shown in Figure 2, after 48 h of treatment 
with methylglyoxal, 28-34% of the worms were at the L3 stage in the control and 0.1 mM 
treatment groups, while this number significantly increased to 77% in the 1 mM 
treatment group. In the control and 0.1 mM treatment group, 56-59% of worms reached 
the L4 stage, but it was 19% in the 1 mM treatment group. These suggested that 1 mM 
methylglyoxal delayed C. elegans’ development from the L3 stage. 
Figure 4. Effect of methylglyoxal on the development of C. elegans. Age-synchronized L1 C. elegans were 
cultured on NGM plates with 0, 0.1, and 1 mM methylglyoxal. The number of worms at each 
developmental stage after 48 h was counted. Values represent means ± S.E. (n=50). ** in the L3 stage 
means significantly different when 1 mM compared with the control and 0.1 mM treatment group (P<0.01). 
** in the L4 stage means significantly different when 1 mM compared with the control and 0.1 mM 
treatment group (P<0.01). 
 
 
4.3. Methylglyoxal treatment significantly reduced body size of C. elegans 
         There was a significant decrease in body length when comparing the treatment 
group to the control (Figure 5). The body width showed consistent results with body 
length, specifically that methylglyoxal treated worms decreased worm width compared to 
the control. Both 0.1 mM and 1 mM methylglyoxal reduced the body size of C. elegans. 
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Importantly, 0.1 mM methylglyoxal exerted this effect on worms without inhibiting their 
growth rate (Figure 4). 
 
 Figure 5. Effect of methylglyoxal on the body size of C. elegans. A: Worm length and B: worm width was 
measured by WormLab software after 48 h treatments. Values represent means ± S.E.(n=50). *** means 
significantly different from control (P<0.001) 
 
 
4.4. Methylglyoxal treatment significantly altered locomotion behaviors of C. 
elegans 
         After exposure to methylglyoxal for 48 h, 0.1 mM of methylglyoxal led to a 
significant increase in the mean speed, while the 1 mM treatment group significantly 
slowed down compared to the control (Figure 6A). However, both 0.1 mM and 1 mM 
treatment groups decreased pharyngeal pumping rates significantly compared to the 
control (Figure 6B). The reduction was 7% and 8% in 0.1 mM and 1 mM methylglyoxal, 
respectively. 
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Figure 6. Effects of methylglyoxal on the locomotion behavior of C. elegans. After treated to 
methylglyoxal for 48 h from L1, A: the average moving speed was measured by WormLab software, and B: 
pharyngeal pumping rate was measured under the optical microscope. Values represent means ± S.E.(n=50). 
* in A means significantly different from control (P<0.05). There is a significant difference between 0.1 
mM and 1 Mm treatment group in A (P<0.001). ** in B means significantly different from control 
(P<0.01). 
 
 
4.5. Heterochronic pathway related gene, lin-41, is involved in the effect of 
methylglyoxal in C. elegans 
In the lin-41 mutants, we found that the developmental period (L1 to adult) was 
reduced to approximately 40 h, while the wild-type worms were approximately 48 h. It 
might be because lin-41 mutant displayed their premature behaviors form the L3 stage 
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(Figure 7A). Besides, the worm length reduced by 45% (Figure 7B), the average speed 
reduced by 59% (Figure 7C), and the pumping rate decreased by 30% (Figure 7D) 
compared to the wild-type worms. The results shown in Figure 7 indicated that there 
were no significant differences on development, body size, and locomotion behaviors 
among the different methylglyoxal treatment groups in the lin-41 mutants.  
 
 
Figure 7. Effects of methylglyoxal on development in the lin-41 mutants. Age-synchronized L1 lin-41 
worms were cultured on NGM plates with 0, 0.1, and 1 mM methylglyoxal. A: The number of worms at 
each developmental stage after 40 h was counted to calculate population percentages of each larval stage. B: 
worm length and C: moving speed of lin-41 mutants were measured by WormLab software when the 
control group worms reached L4/young adult after 40 h treatments. D: Pharyngeal pumping rate was 
counted under optical microscope. Values represents means ± S.E. (n=50 in A, B, & C, n=12 in D). 
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4.6. Discussion 
In the present research, methylglyoxal at 1 mM significantly decreased lifespan and 
delayed development of C. elegans. Furthermore, methylglyoxal at 0.1 mM displayed 
effects on worm body size and locomotion behaviors. The lin-41 mutant abolished the 
effects of methylglyoxal on development, worm body size, and locomotion behaviors, at 
both 0.1 mM and 1 mM, suggesting that this heterochronic pathway is a target of 
methylglyoxal's effect. 
In previous studies, Drosophila melanogaster upon methylglyoxal treatment 
significantly reduced its maximum lifespan in a dose-dependent manner from 5 mM to 50 
mM, where 10 mM of methylglyoxal reduced 48% of the median lifespan (Guelinckx et 
al., 2008). However, the current study showed that 1 mM methylglyoxal reduced 33% of 
the maximum lifespan of C. elegans compared to the control group, which suggested that 
C. elegans is more susceptible to methylglyoxal than Drosophila melanogaster. 
Locomotion is a natural behavior that the worm’s movement exhibits as an 
undulatory motion produced by waves of muscular contraction and relaxation regulated 
by the nervous system (Burr et al., 2004). The results of this research indicated that the 
average moving speeds of methylglyoxal-treated worms depends on concentrations of the 
compound. This type of response was similar to those overserved in Parkinson's disease, 
which include periods of abnormally high (rigidity) and then low (bradykinesia) motor 
activity. Thus, it would be important to investigate effects of methylglyoxal in the 
nervous system in the future.  
The control of pharyngeal pumping rate is a complex process that involves both the 
pharyngeal muscle cells and neurons that innervate the pharynx. The obvious reduction 
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of pumping rate by methylglyoxal could be a cause for retarded development. However, 
in this research, the significant reduction of pumping rate was not consistent with the 
developmental delay at 0.1 and 1 mM, which suggests that there would be at least two 
distinctive pathways involved in methylglyoxal's effects on these. 
Growth rate under microscopic observation is the most direct parameter of 
development due to specific developmental events: the L1/L2 molt and the start of 
oogenesis in young adult C. elegans. Corresponding with lifespan data, growth was 
delayed significantly when the concentration of methylglyoxal was increased to 1 mM. 
The current results showed both 0.1 mM and 1 mM of methylglyoxal causing significant 
reductions in worm length and width. Since most of the worms (77 %) were at the L3 
stage upon 1 mM treatment, compared to 28-34 % of worms at the L4 stage of control 
and 0.1 mM treatment, the reduced worm sizes may result from the retarded development 
stage. However, without interferencing by development delayed, low dose at 0.1 mM 
methylglyoxal still exerted its effect on body sizes. 
In C. elegans, lin-41 encodes a RING-finger B-box Coiled-coil-containing protein 
and is involved in the heterochronic pathway, which temporally control the timing of 
each larval stage (Solomon et al., 2008). The let-7 microRNAs, which takes effect on the 
L2-to-L3 transition, regulates lin-41 negatively. More importantly, lin-41 represses lin-29, 
the most direct regulator of the larval to adult transition in C. elegans, to prevent terminal 
differentiation of hypodermal seam cells (Reinhart et al., 2000). Thus, lin-41 loss-of-
function mutants would display premature phenotypes at the L3 larval stage and secrete 
adult alae ahead of time, but would have normal L1 and L2 stage fates (Reinhart et al., 
2000; Solomon et al., 2008). The current study showed that lin-41 mutants abolished all 
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the effects of methylglyoxal on development, suggesting that methylglyoxal delays 
development through the heterochronic pathway, particularly lin-41. 
      
 29 
 
REFERENCES 
Abbott, A.L., Alvarez-Saavedra, E., Miska, E.A., Lau, N.C., Bartel, D.P., Horvitz, H.R. 
and Ambros, V., 2005. The let-7 MicroRNA family members mir-48, mir-84, and 
mir-241 function together to regulate developmental timing in Caenorhabditis 
elegans. Developmental Cell 9, 403-414.  
Ahmed, N., Battah, S., Karachalias, N., Babaei-Jadidi, R., Horányi, M., Baróti, K., 
Hollan, S. and Thornalley, P.J., 2003a. Increased formation of methylglyoxal and 
protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. 
Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease 1639, 121-132.  
Ahmed, N., Thornalley, P.J., Dawczynski, J., Franke, S., Strobel, J., Stein, G. and Haik, 
G.M., 2003b. Methylglyoxal-derived hydroimidazolone advanced glycation end-
products of human lens proteins. Investigative Ophthalmology & Visual Science 44, 
5287-5292.  
Ambros, V. and Horvitz, H., 1984. Heterochronic mutants of the nematode. Science 226, 
409-416.  
Apple, M.A. and Greenberg, D.M., 1968. Arrest of cancer in mice by therapy with 
normal metabolites. II. Indefinite survirors among mice treated with mixtures of 2-
oxopropanal (NSC-79019) and 2,3-dihydroxypropanal (NSC67934). Cancer 
Chemotherapy Reports 52, 687-696.  
Bierhaus, A., Humpert, P.M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, 
D.M. and Nawroth, P.P., 2005. Understanding RAGE, the receptor for advanced 
glycation end products. Journal of Molecular Medicine 83, 876-886.  
Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, 
M.C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van 
Swieten, J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A. and Heutink, P., 
2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset 
parkinsonism. Science 299, 256-259 doi: 10.1126/science.1077209 [doi].  
Burr, A., Robinson, A.F., Gaugler, R. and Bilgrami, A., 2004. Locomotion behaviour. 
Nematode Behaviour, 25-62.  
Chakraborty, S., Karmakar, K. and Chakravortty, D., 2014. Cells producing their own 
nemesis: understanding methylglyoxal metabolism. IUBMB Life 66, 667-678.  
Chan, W., Wu, H. and Shiao, N., 2007. Apoptotic signaling in methylglyoxal‐treated 
human osteoblasts involves oxidative stress, c‐Jun N‐terminal kinase, caspase‐3, and 
p21‐activated kinase 2. Journal of Cellular Biochemistry 100, 1056-1069.  
 30 
 
Choudhary, D., Chandra, D. and Kale, R.K., 1997. Influence of methylglyoxal on 
antioxidant enzymes and oxidative damage. Toxicology Letters 93, 141-152.  
Cooper, R., 1984. Metabolism of methylglyoxal in microorganisms. Annual Reviews in 
Microbiology 38, 49-68.  
Corey, E.J., Gilman, N.W. and Ganem, B., 1968. New methods for the oxidation of 
aldehydes to carboxylic acids and esters. Journal of the American Chemical Society 
90, 5616-5617.  
Coulson, A., Kozono, Y., Lutterbach, B., Shownkeen, R., Sulston, J. and Waterston, R., 
1991. YACs and the C. elegans genome. Bioessays 13, 413-417.  
Dakin, H. and Dudley, H., 1913. The intercoversion of α-amino-acids, α-hydroxy-acids 
and α-ketonic aldehydes. Part II. Journal of Biological Chemistry 15, 127-143.  
Degen, J., Hellwig, M. and Henle, T., 2012. 1, 2-Dicarbonyl compounds in commonly 
consumed foods. Journal of Agricultural and Food Chemistry 60, 7071-7079.  
Dimitriadi, M. and Hart, A.C., 2010. Neurodegenerative disorders: insights from the 
nematode Caenorhabditis elegans. Neurobiology of Disease 40, 4-11.  
Fujioka, K. and Shibamoto, T., 2004. Formation of genotoxic dicarbonyl compounds in 
dietary oils upon oxidation. Lipids 39, 481.  
Giles, A.C. and Rankin, C.H., 2009. Behavioral and genetic characterization of 
habituation using Caenorhabditis elegans. Neurobiology of Learning and Memory 
92, 139-146.  
Golej, J., Hoeger, H., Radner, W., Unfried, G. and Lubec, G., 1998. Oral administration 
of methylglyoxal leads to kidney collagen accumulation in the mouse. Life Sciences 
63, 801-807.  
Greer, E.R., Perez, C.L., Van Gilst, M.R., Lee, B.H. and Ashrafi, K., 2008. Neural and 
molecular dissection of a C. elegans sensory circuit that regulates fat and feeding. 
Cell Metabolism 8, 118-131.  
Guelinckx, I., Devlieger, R., Beckers, K. and Vansant, G., 2008. Maternal obesity: 
pregnancy complications, gestational weight gain and nutrition. Obesity Reviews 9, 
140-150 doi: 10.1111/j.1467-789X.2007.00464. x.  
Helmcke, K.J., Syversen, T., Miller, D.M. and Aschner, M., 2009. Characterization of the 
effects of methylmercury on Caenorhabditis elegans. Toxicology and Applied 
Pharmacology 240, 265-272.  
 31 
 
Jadhav, K.B. and Rajini, P., 2009. Neurophysiological alterations in Caenorhabditis 
elegans exposed to dichlorvos, an organophosphorus insecticide. Pesticide 
Biochemistry and Physiology 94, 79-85.  
Kalapos, M.P., 1999. Methylglyoxal in living organisms: chemistry, biochemistry, 
toxicology and biological implications. Toxicology Letters 110, 145-175.  
Kalapos, M.P., Littauer, A. and qde Groot, H., 1993. Has reactive oxygen a role in 
methylglyoxal toxicity? A study on cultured rat hepatocytes. Archives of 
Toxicology 67, 369-372.  
Kalapos, M.P., Schaff, Z., Garzó, T., Antoni, F. and Mandl, J., 1991. Accumulation of 
phenols in isolated hepatocytes after pretreatment with methylglyoxal. Toxicology 
Letters 58, 181-191.  
Kaletta, T. and Hengartner, M.O., 2006. Finding function in novel targets: C. elegans as a 
model organism. Nature Reviews Drug Discovery 5, 387-399.  
Kisch, B., 1932. Beeinflussung der gewebsatmung durch methylglyoxal. Biochemische 
Zeitschrift 253, 373-376.  
Ko, J., Kim, I., Yoo, S., Min, B., Kim, K. and Park, C., 2005. Conversion of 
methylglyoxal to acetol by Escherichia coli aldo-keto reductases. Journal of 
Bacteriology 187, 5782-5789 doi: 187/16/5782 [pii].  
Kupari, M., Lommi, J., Ventilä, M. and Karjalainen, U., 1995. Breath acetone in 
congestive heart failure. The American Journal of Cardiology 76, 1076-1078.  
L’Hernault, S.W., 2009. The genetics and cell biology of spermatogenesis in the 
nematode C. elegans. Molecular and Cellular Endocrinology 306, 59-65.  
Lee, R.C., Feinbaum, R.L. and Ambros, V., 1993. The C. elegans heterochronic gene lin-
4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854.  
Lee, J.Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., Kim, J. and Park, C., 2012. 
Human DJ-1 and its homologs are novel glyoxalases. Human Molecular Genetics 21, 
3215-3225 doi: 10.1093/hmg/dds155 [doi].  
Leung, M.C., Williams, P.L., Benedetto, A., Au, C., Helmcke, K.J., Aschner, M. and 
Meyer, J.N., 2008. Caenorhabditis elegans: an emerging model in biomedical and 
environmental toxicology. Toxicological Sciences: An Official Journal of The 
Society of Toxicology 106, 5-28 doi: 10.1093/toxics/kfn121 [doi].  
Lo, T.W., Westwood, M.E., McLellan, A.C., Selwood, T. and Thornalley, P.J., 1994. 
Binding and modification of proteins by methylglyoxal under physiological 
conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-
 32 
 
acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. The Journal of 
Biological Chemistry 269, 32299-32305.  
Martins, S.I., Marcelis, A.T. and van Boekel, M.A., 2003. Kinetic modelling of Amadori 
N-(1-deoxy-D-fructos-1-yl)-glycine degradation pathways. Part I—Reaction 
mechanism. Carbohydrate Research 338, 1651-1663.  
Mavric, E., Wittmann, S., Barth, G. and Henle, T., 2008. Identification and quantification 
of methylglyoxal as the dominant antibacterial constituent of Manuka 
(Leptospermum scoparium) honeys from New Zealand. Molecular Nutrition & Food 
Research 52, 483-489.  
Morcos, M., Du, X., Pfisterer, F., Hutter, H., Sayed, A.A., Thornalley, P., Ahmed, N., 
Baynes, J., Thorpe, S. and Kukudov, G., 2008. Glyoxalase‐1 prevents mitochondrial 
protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7, 
260-269.  
Nagao, M., Fujita, Y., Wakabayashi, K., Nukaya, H., Kosuge, T. and Sugimura, T., 1986. 
Mutagens in coffee and other beverages. Environmental Health Perspectives 67, 89-
91.  
Nemet, I., Varga‐Defterdarović, L. and Turk, Z., 2006. Methylglyoxal in food and living 
organisms. Molecular Nutrition & Food Research 50, 1105-1117.  
Niyati-Shirkhodaee, F. and Shibamoto, T., 1993. Gas chromatographic analysis of 
glyoxal and methylglyoxal formed from lipids and related compounds upon 
ultraviolet irradiation. Journal of Agricultural and Food Chemistry 41, 227-230.  
Pepper, A.S., McCane, J.E., Kemper, K., Yeung, D.A., Lee, R.C., Ambros, V. and Moss, 
E.G., 2004. The C. elegans heterochronic gene lin-46 affects developmental timing 
at two larval stages and encodes a relative of the scaffolding protein gephyrin. 
Development 131, 2049-2059 doi: 10.1242/dev.01098 [doi].  
Rabbani, N. and Thornalley, P.J., 2012. Methylglyoxal, glyoxalase 1 and the dicarbonyl 
proteome. Amino Acids 42, 1133-1142.  
Rabbani, N., Xue, M. and Thornalley, P.J., 2016. Methylglyoxal-induced dicarbonyl 
stress in aging and disease: first steps towards glyoxalase 1-based treatments. 
Clinical Science (London, England: 1979) 130, 1677-1696 doi: 
10.1042/CS20160025 [doi].  
Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., 
Horvitz, H.R. and Ruvkun, G., 2000. The 21-nucleotide let-7 RNA regulates 
developmental timing in Caenorhabditis elegans. Nature 403, 901-906.  
 33 
 
Rougvie, A.E. and Ambros, V., 1995. The heterochronic gene lin-29 encodes a zinc 
finger protein that controls a terminal differentiation event in Caenorhabditis elegans. 
Development 121, 2491-2500.  
Shashikumar, S. and Rajini, P., 2010. Cypermethrin elicited responses in heat shock 
protein and feeding in Caenorhabditis elegans. Ecotoxicology and Environmental 
safety 73, 1057-1062.  
Shen, L., Xiao, J., Ye, H. and Wang, D., 2009. Toxicity evaluation in nematode 
Caenorhabditis elegans after chronic metal exposure. Environmental Toxicology and 
Pharmacology 28, 125-132.  
Shimizu, Y., Sakuraba, H., Kawakami, R., Goda, S., Kawarabayasi, Y. and Ohshima, T., 
2005. L-Threonine dehydrogenase from the hyperthermophilic archaeon Pyrococcus 
horikoshii OT3: gene cloning and enzymatic characterization. Extremophiles 9, 317-
324.  
Shinohara, M., Thornalley, P.J., Giardino, I., Beisswenger, P., Thorpe, S.R., Onorato, J. 
and Brownlee, M., 1998. Overexpression of glyoxalase-I in bovine endothelial cells 
inhibits intracellular advanced glycation endproduct formation and prevents 
hyperglycemia-induced increases in macromolecular endocytosis. The Journal of 
Clinical Investigation 101, 1142-1147 doi: 10.1172/JCI119885 [doi].  
Singh, R., Barden, A., Mori, T. and Beilin, L., 2001. Advanced glycation end-products: a 
review. Diabetologia 44, 129-146.  
Sjolemma, B. and Seekles, L., 1926. Über die Zuckerbildung aus dem Methylglyoxal in 
normalen Tierkörper. Biochemische Zeitschrift 176, 431-440.  
Slack, F.J., Basson, M., Liu, Z., Ambros, V., Horvitz, H.R. and Ruvkun, G., 2000. The 
lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 
regulatory RNA and the LIN-29 transcription factor. Molecular Cell 5, 659-669.  
Solomon, A., Mian, Y., Ortega-Cava, C., Liu, V.W.T., Gurumurthy, C.B., Naramura, M., 
Band, V. and Band, H., 2008. Upregulation of the let-7 microRNA with precocious 
development in lin-12/Notch hypermorphic Caenorhabditis elegans mutants. 
Developmental Biology 316, 191-199.  
Sulston, J.E., Schierenberg, E., White, J.G. and Thomson, J., 1983. The embryonic cell 
lineage of the nematode Caenorhabditis elegans. Developmental Biology 100, 64-
119.  
Sulston, J.E. and Horvitz, H.R., 1977. Post-embryonic cell lineages of the nematode, 
Caenorhabditis elegans. Developmental Biology 56, 110-156.  
 34 
 
Tan, D., Wang, Y., Lo, C., Sang, S. and Ho, C., 2008. Methylglyoxal: its presence in 
beverages and potential scavengers. Annals of The New York Academy of Sciences 
1126, 72-75.  
Tejeda-Benitez, L. and Olivero-Verbel, J., 2016. Caenorhabditis elegans, a biological 
model for research in toxicology. Reviews of Environmental Contamination and 
Toxicology Volume 237 pp. 1-35.  
Thornalley, P., Wolff, S., Crabbe, J. and Stern, A., 1984. The autoxidation of 
glyceraldehyde and other simple monosaccharides under physiological conditions 
catalysed by buffer ions. Biochimica Et Biophysica Acta (BBA)-General Subjects 
797, 276-287.  
Thornalley, P.J. and Rabbani, N., 2010. Dicarbonyls in cola drinks sweetened with 
sucrose or high fructose corn syrup. Maillard Reaction: Interface Between Aging, 
Nutrition and Metabolism, 158-163.  
Thornalley, P.J., 1996. Pharmacology of methylglyoxal: formation, modification of 
proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and 
antiproliferative chemotherapy. General Pharmacology: The Vascular System 27, 
565-573.  
Thornalley, P.J., 1995. Advances in glyoxalase research. Glyoxalase expression in 
malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor 
diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding 
and endocytosis by the advanced glycation endproduct receptor. Critical Reviews in 
Oncology/Hematology 20, 99-128.  
Thornalley, P.J., Langborg, A. and Minhas, H.S., 1999. Formation of glyoxal, 
methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. The 
Biochemical Journal 344 Pt 1, 109-116.  
Thornalley, P.J., 1990. The glyoxalase system: new developments towards functional 
characterization of a metabolic pathway fundamental to biological life. The 
Biochemical Journal 269, 1-11.  
Vander Jagt, D.L. and Hunsaker, L.A., 2003. Methylglyoxal metabolism and diabetic 
complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde 
dehydrogenase and 2-oxoaldehyde dehydrogenase. Chemico-biological Interactions 
143, 341-351.  
Veech, R.L., 2004. The therapeutic implications of ketone bodies: the effects of ketone 
bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin 
resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes and 
Essential Fatty Acids 70, 309-319.  
 35 
 
Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M. and Aldini, G., 2013. 
Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an 
overview of their mechanisms of formation. Free Radical Research 47, 3-27.  
Wang, D., Liu, P., Yang, Y. and Shen, L., 2010. Formation of a combined Ca/Cd toxicity 
on lifespan of nematode Caenorhabditis elegans. Ecotoxicology and Environmental 
Safety 73, 1221-1230.  
Weigel, K.U., Opitz, T. and Henle, T., 2004. Studies on the occurrence and formation of 
1, 2-dicarbonyls in honey. European Food Research and Technology 218, 147-151.  
White, J.G., Southgate, E., Thomson, J.N. and Brenner, S., 1986. The structure of the 
nervous system of the nematode Caenorhabditis elegans. Philosophical Transactions 
of the Royal Society B: Biological Sciences 314, 1-340.  
Wu, Q., He, K., Liu, P., Li, Y. and Wang, D., 2011. Association of oxidative stress with 
the formation of reproductive toxicity from mercury exposure on hermaphrodite 
nematode Caenorhabditis elegans. Environmental Toxicology and Pharmacology 32, 
175-184.  
Yadav, S.K., Singla-Pareek, S.L., Ray, M., Reddy, M. and Sopory, S., 2005. 
Methylglyoxal levels in plants under salinity stress are dependent on glyoxalase I 
and glutathione. Biochemical and Biophysical Research Communications 337, 61-
67.  
Yu, Z., Chen, X., Zhang, J., Wang, R. and Yin, D., 2013. Transgenerational effects of 
heavy metals on L3 larva of Caenorhabditis elegans with greater behavior and 
growth inhibitions in the progeny. Ecotoxicology and Environmental Safety 88, 178-
184.  
Yunhui, L., Yang, W., Lihong, Y., Yuepu, P. and Dayong, W., 2009. Using the nematode 
Caenorhabditis elegans as a model animal for assessing the toxicity induced by 
microcystin-LR. Journal of Environmental Sciences 21, 395-401.  
Zhuang, Z., Zhao, Y., Wu, Q., Li, M., Liu, H., Sun, L., Gao, W. and Wang, D., 2014. 
Adverse effects from clenbuterol and ractopamine on nematode Caenorhabditis 
elegans and the underlying mechanism. PloS one 9, e85482.  
 
